119 related articles for article (PubMed ID: 37960718)
21. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
22. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
24. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
25. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Zhong Z; Xu M; Tan J
Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
[No Abstract] [Full Text] [Related]
26. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
27. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
28. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
29. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
Gao B; Wang Y; Li C; Lu S
Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
[TBL] [Abstract][Full Text] [Related]
30. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
31. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
33. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden.
Tang B; Zhu J; Zhao Z; Lu C; Liu S; Fang S; Zheng L; Zhang N; Chen M; Xu M; Yu R; Ji J
J Adv Res; 2021 Nov; 33():153-165. PubMed ID: 34603786
[TBL] [Abstract][Full Text] [Related]
35. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
36. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
38. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
39. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.
Wang Z; Zhang N; Lv J; Ma C; Gu J; Du Y; Qiu Y; Zhang Z; Li M; Jiang Y; Zhao J; Du H; Zhang Z; Lu W; Zhang Y
Biomed Res Int; 2020; 2020():4037639. PubMed ID: 33163533
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
Wang D; Ding D; Ying J; Qin Y
IET Syst Biol; 2023 Dec; 17(6):366-377. PubMed ID: 37935646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]